A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Novo Cure LTD stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 525 shares of NVCR stock, worth $16,259. This represents 0.0% of its overall portfolio holdings.

Number of Shares
525
Previous 509 3.14%
Holding current value
$16,259
Previous $8,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$15.61 - $23.34 $249 - $373
16 Added 3.14%
525 $8,000
Q2 2024

Jul 05, 2024

BUY
$11.83 - $24.05 $6,021 - $12,241
509 New
509 $8,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.25B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Thurston, Springer, Miller, Herd & Titak, Inc. Portfolio

Follow Thurston, Springer, Miller, Herd & Titak, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thurston, Springer, Miller, Herd & Titak, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Thurston, Springer, Miller, Herd & Titak, Inc. with notifications on news.